Strengths Limitations Study-level data Literature review  Easy and inexpensive  Reviews can be conducted relatively quickly  Studies subject to peer-review process  Only useful if the published data are reported from patient populations directly comparable with those receiving the new therapy, with outcomes, prognostic variables, and other key variables defined in a similar manner  Standard of care treatments may change over time  Unlikely to be valid in rare diseases
 Comparability depends upon similarities in study populations and definitions of outcomes between studies in the metaanalysis and studies in the new treatment  Heterogeneity across studies in the meta-analysis presents difficulties in how to interpret appropriateness of summarizing outcomes Single-center experience  Relatively easy and inexpensive  Data available at patient level and can be harmonized to clinical trial data for new therapy subjects  Only useful if the single centre data are reported from patient populations directly comparable with those receiving the new therapy, with outcomes, prognostic variables, and other key variables defined in a similar manner  May not reflect general clinical practice Patient-level data Pooled analysis -weighted or unweighted  More precise and robust than study-level analyses  Allows for standardization of variables and application of specific patient selection criteria across different sites  Provides potential for data that are more comparable to the patient population receiving the new therapy  Data may be collected differently between the historical studies and studies with new therapies, and key study variables may be defined differently  Large differences in study populations may make comparisons difficult  Standard of care treatments may change over time 
